Powered by Guardant Infinity™
Fastest, tissue-free MRD test
for all stages of colorectal, breast, and lung cancers.1-5
Analyze thousands of epigenomic signals to achieve high sensitivity without tissue dependency.1,2
Tumor fraction based on methylation to accurately quantify disease burden1
Timely results
in 7 days6*
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
MRD, minimal residual disease.
*Median turnaround time from sample receipt to results.
†Guardant Reveal is covered by Medicare for all CRC patients being treated with curative intent—for both adjuvant therapy decision-making after surgery and longitudinal surveillance every 3 to 6 months.
Medicare-covered for post-surgery and surveillance†